Bullboard Post History

by ScienceFirst

Order by:

V.TLT	RE:total addressable market (“TAM”) = 500,000 patients TLT's treatment is not going the complicated route (BLA) that ImmunityBio... March 9, 2023
V.TLT	RE:total addressable market (“TAM”) = 500,000 patients Even before Keytruda turned in disappointing response rates, the... March 9, 2023
T.PYR	RE:RE:PYR held up very well today It's Tamarackflop's friend that arranged to sell @0.99$US in the last... March 9, 2023
V.TLT	total addressable market (“TAM”) = 500,000 patients Interesting numbers, from an article on ImmunityBio that targets the same... March 9, 2023
V.TLT	RE:Project Frontrunner I already documented this, just like project Orbis. Frontrunner would allow... March 9, 2023
T.PYR	RE:RE:PYR held up very well today Tamarackflop silences the fact that despite the 524 buyers @1.41 and only 24... March 9, 2023
T.PYR	RE:Biggest clown? Tamarackflop tried so hard, every single, for months, to scare us with its... March 9, 2023
T.PYR	UncleClown missed 100% of his targets Amazing how this clown keeps saying that he's always right, when he's... March 9, 2023
T.PYR	Where’s our clown Tamarackflop? No more daily FUD??? March 9, 2023
V.TLT	RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:It takes money to advance oncology R&D Couldn't agree more with you Gebremeskel. And some would be more... March 9, 2023
V.TLT	RE:RE:RE:RE:RE:RE:RE:It takes money to advance oncology R&D Our dinosaur and grumbler-in-chief FGPStuck is at it again!!! It is TLT... March 8, 2023
T.PYR	RE:What I really don't get There's a lot of things that Tamarackflop doesn't understand. The... March 8, 2023
V.TLT	RE:Roche’s 3-for-1 opportunity clearly, I don't know why big pharmas are so stubborn with immunotherapy.... March 7, 2023
V.TLT	RE:Roche’s 3-for-1 opportunity Roche failed in NSCLC May 2022 Closely watched Roche drug fails a second... March 7, 2023
V.TLT	RE:Roche’s 3-for-1 opportunity Roche in NSCLC: Health Canada Authorizes TECENTRIQ® (atezolizumab... March 7, 2023
V.TLT	RE:Roche’s 3-for-1 opportunity Roche in GBM. They could probably combo with us in another GBM study ... March 7, 2023
V.TLT	Roche’s 3-for-1 opportunity Wanted to penetrate the bladder market but failed. They now have a 2nd... March 7, 2023
V.TLT	RE:RE:RE:RE:RE:It takes money to advance oncology R&D Novartis is already targeting NMIBC and NSCLC. So not necessarily the... March 7, 2023
V.TLT	RE:It takes money to advance oncology R&D I have no official proof that a pp is in the making but yesterday's... March 7, 2023
V.TLT	Roche is my take as our NMIBC jv partner Pfizer and Merck seem to have other plans. At least, for what we've... March 7, 2023

Become a member today, It's free!

Bullboard Post History

by ScienceFirst

RE:total addressable market (“TAM”) = 500,000 patients

RE:total addressable market (“TAM”) = 500,000 patients

RE:RE:PYR held up very well today

total addressable market (“TAM”) = 500,000 patients

RE:Project Frontrunner

RE:RE:PYR held up very well today

RE:Biggest clown?

UncleClown missed 100% of his targets

Where’s our clown Tamarackflop?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:It takes money to advance oncology R&D

RE:RE:RE:RE:RE:RE:RE:It takes money to advance oncology R&D

RE:What I really don't get

RE:Roche’s 3-for-1 opportunity

RE:Roche’s 3-for-1 opportunity

RE:Roche’s 3-for-1 opportunity

RE:Roche’s 3-for-1 opportunity

Roche’s 3-for-1 opportunity

RE:RE:RE:RE:RE:It takes money to advance oncology R&D

RE:It takes money to advance oncology R&D

Roche is my take as our NMIBC jv partner

Featured News Links

Options Trading for Retiring: Key Strategies in Balancing Retirement Income

One Property, One Focus on Advancing this Gold Project in Ontario

Featured Company

Revive Therapeutics Ltd C.RVV

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard Post History

by ScienceFirst

Featured News Links

Featured Company